Barclays Raises Hims & Hers Target After Novo Deal Clears
Barclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
Uncover the best high cash back cards that charge no annual fees. Maximize your rewards while keeping your costs down.
28,270 articlesBarclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
Oklo faces a pivotal moment after July. This piece explains a single catalyst investors should watch, the potential s...
Marvell Technology tumbles on revised AI capex forecasts, intensifying a wider retreat in semiconductor names. Major ...
A rising concentration in a handful of tech names is signaling a wall street flashing warning for many investors. Thi...
When a legendary investor shifts big positions, traders sit up. This piece breaks down what it could mean that billio...
Could Oracle become America’s next $1 trillion tech stock? This article weighs the growth catalysts, headwinds, and a...
The 2026 IPO boom is broadening beyond AI megadeals as mid-cap and overlooked sectors attract new capital. A busy sec...
Oracle’s Stargate initiative in Texas stalls amid financing questions and evolving AI compute needs, rattling investo...
The Trade Desk has faced a tough stretch, but patient investors are asking if the trade desk stock finally offers a p...
SpaceX is poised to make a historic move into public markets. This guide breaks down what retail investors should kno...
Bitcoin tumbled to the low $71,000s on June 1, 2026, as geopolitical tensions sparked a wave of liquidations across c...
Powell's departure marks more than a leadership change. A divided FOMC and a market still riding AI-driven highs crea...